OBJECTIVES To contribute to current discussions about budget impact modeling, two different approaches for the impact of a new pharmaceutical product were analyzed: firstly considering the impact on annual healthcare expenditures only, and secondly additional inclusion of lost insurance premiums due to possible early retirement in patients with chronic diseases. METHODS The dynamic model calc...

Cost-effectiveness analysis (CEA) – which in certain cases is used interchangeably with the term cost-utility through use of QALY-has been established as pinnacle decision-makin...